We are live on ! Find out more
SCV

Sands Capital Ventures Portfolio holdings

AUM $614M
1-Year Est. Return 19.92%
This Fund
S&P 500
This Quarter Est. Return
-5.98%
1 Year Est. Return
+19.92%
3 Year Est. Return
+166.76%
5 Year Est. Return
+157.76%
10 Year Est. Return
–
AUM
$299M
AUM Growth
-$116M
Cap. Flow
-$68.3M
Cap. Flow %
-22.87%
Top 10 Hldgs %
98.59%
Holding
20
New
–
Increased
3
Reduced
7
Closed
–

Top Buys

Rank Stock Value
1
ACRV icon
Acrivon Therapeutics
ACRV
+$3.79M
2
KVYO icon
Klaviyo
KVYO
+$31K
3
IOT icon
Samsara
IOT
+$23.1K

Top Sells

Rank Stock Value
1
NU icon
Nu Holdings
NU
+$21.3M
2
PATH icon
UiPath
PATH
+$19.9M
3
SNOW icon
Snowflake
SNOW
+$15.8M
4
DASH icon
DoorDash
DASH
+$12M
5
CADL icon
Candel Therapeutics
CADL
+$3.05M

Sector Composition

Rank Sector Weight
1 Technology 39.29%
2 Financials 31.64%
3 Consumer Discretionary 15.5%
4 Healthcare 13.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NU icon
1
Nu Holdings
NU
$73.6B
$94.5M 31.64%
7,328,294
-1,827,367
-20% -$21.3M
KVYO icon
2
Klaviyo
KVYO
$5.26B
$87.5M 29.31%
3,516,221
+1,324
+0% +$31K
DASH icon
3
DoorDash
DASH
$94B
$46M 15.41%
423,091
-100,000
-19% -$12M
PATH icon
4
UiPath
PATH
$8.3B
$14.6M 4.91%
1,155,246
-1,148,206
-50% -$19.9M
SNOW icon
5
Snowflake
SNOW
$114B
$14.6M 4.9%
108,304
-107,311
-50% -$15.8M
ACRV icon
6
Acrivon Therapeutics
ACRV
$83.6M
$12.3M 4.12%
2,122,605
+470,000
+28% +$3.79M
TXG icon
7
10x Genomics
TXG
$7.31B
$9.37M 3.14%
481,770
– –
ABOS icon
8
Acumen Pharmaceuticals
ABOS
$193M
$8.27M 2.77%
3,417,075
– –
TARS icon
9
Tarsus Pharmaceuticals
TARS
$3.04B
$4.62M 1.55%
170,000
– –
CADL icon
10
Candel Therapeutics
CADL
$897M
$2.52M 0.84%
405,837
-405,900
-50% -$3.05M
TSHA icon
11
Taysha Gene Therapies
TSHA
$1.94B
$1.62M 0.54%
724,873
– –
MASS icon
12
908 Devices
MASS
$414M
$1.22M 0.41%
237,258
– –
SPRB
13
Spruce Biosciences
SPRB
$151M
$409K 0.14%
10,493
– –
CPNG icon
14
Coupang
CPNG
$29B
$250K 0.08%
11,931
– –
ABSI icon
15
Absci
ABSI
$1.58B
$178K 0.06%
57,804
– –
IOT icon
16
Samsara
IOT
$23.2B
$143K 0.05%
4,239
+669
+19% +$23.1K
DDOG icon
17
Datadog
DDOG
$91.7B
$132K 0.04%
1,015
– –
TOST icon
18
Toast
TOST
$20.1B
$127K 0.04%
4,945
-1,002
-17% -$24.2K
CRWD icon
19
CrowdStrike
CRWD
$221B
$84.7K 0.03%
884
-232
-21% -$19.3K
GTLB icon
20
GitLab
GTLB
$7.2B
$32.7K 0.01%
658
– –

Similar funds

T2I
Turim 21 Investimentos Rio De Janeiro, Brazil $613M AUM 14.25% 1-Year Est. Return
VAG
VisionPoint Advisory Group Dallas, Texas $613M AUM 30.37% 1-Year Est. Return
MKA
M. Kulyk & Associates Decatur, Georgia $613M AUM 22.75% 1-Year Est. Return
CSIA
Conrad Siegel Investment Advisors Harrisburg, Pennsylvania $615M AUM 21.19% 1-Year Est. Return
ATFA
All Terrain Financial Advisors Coon Rapids, Minnesota $615M AUM 30.42% 1-Year Est. Return
AA
Aire Advisors Beverly Hills, California $615M AUM 25.07% 1-Year Est. Return
FWM
Fonville Wealth Management Richmond, Virginia $612M AUM 18.82% 1-Year Est. Return
FSA
Financial Security Advisor Virginia Beach, Virginia $615M AUM 26.08% 1-Year Est. Return

Sands Capital Ventures's Q2 2024 Portfolio in Review

As of Q2 2024, Sands Capital Ventures held 20 positions worth $299M, down 28% from $415M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Sands Capital Ventures withdrew a net $68.3M in Q2 2024, reducing 7 holdings. Its largest reduction was Nu Holdings, cutting an estimated $21.3M.

By sector, the portfolio is most concentrated in Technology at 39% of assets, down from 43% a quarter earlier, followed by Financials and Consumer Discretionary.

Against the trend, Sands Capital Ventures added an estimated $3.79M to Acrivon Therapeutics.

  • Sands Capital Ventures added most to Acrivon Therapeutics in Q2 2024, an estimated $3.79M increase.
  • Sands Capital Ventures's biggest Q2 2024 reduction was Nu Holdings, cutting an estimated $21.3M.
  • Sands Capital Ventures's ten largest holdings make up 99% of its $299M portfolio in Q2 2024.
  • Sands Capital Ventures opened 0 new positions and closed 0 in Q2 2024.
  • Sands Capital Ventures's portfolio value fell 28% quarter-over-quarter to $299M.

Based on Sands Capital Ventures's 13F filing for Q2 2024, filed 13 Aug 2024.